Cited by 103Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and ResearchDiabetes Treatment and Management

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Association between pre-diabetes and microvascular and macrovascular disease in newly diagnosed type 2 diabetes

Open access

Abstract

Objective: The associated risk of vascular disease following diagnosis of type 2 diabetes in people previously identified as having pre-diabetes in real-world settings is unknown. We examined the presence of microvascular and macrovascular disease in individuals with newly diagnosed type 2 diabetes by glycemic status within 3 years before diagnosis. Research design and methods: We identified 159 736 individuals with newly diagnosed type 2 diabetes from the UK Clinical Practice Research Datalink database in England between 2004 and 2017. We used logistic regression models to compare presence of microvascular (retinopathy and nephropathy) and macrovascular (acute coronary syndrome, cerebrovascular and peripheral arterial disease) disease at the time of type 2 diabetes diagnosis by prior glycemic status. Results: Half of the study population (49.9%) had at least one vascular disease, over one-third (37.4%) had microvascular disease, and almost a quarter (23.5%) had a diagnosed macrovascular disease at the time of type 2 diabetes diagnosis. Compared with individuals with glycemic values within the normal range, those detected with pre-diabetes before the diagnosis had 76% and 14% increased odds of retinopathy and nephropathy (retinopathy: adjusted OR (AOR) 1.76, 95% CI 1.69 to 1.85; nephropathy: AOR 1.14, 95% CI 1.10 to 1.19), and 7% higher odds of the diagnosis of acute coronary syndrome (OR 1.07, 95% CI 1.03 to 1.12) in fully adjusted models at time of diabetes diagnosis. Conclusions: Microvascular and macrovascular diseases are detected in 37%–24% of people with newly diagnosed type 2 diabetes. Pre-diabetes before diagnosis of type 2 diabetes is associated with increased odds of microvascular disease and acute coronary syndrome. Detection of pre-diabetes might represent an opportunity for reducing the burden of microvascular and macrovascular disease through heightened attention to screening for vascular complications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjdrc-2019-001061

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Prevalence of microvascular (retinopathy and nephropathy) and macrovascular (acute coronary syndrome, cerebrovascular, and peripheral arterial disease) diseases present at time of the diagnosis of type 2 diabetes according to glycemic status in the 3 years before the diagnosis of type 2 diabetes. A microvascular disease was considered being present at time of type 2 diabetes diagnosis if the condition was diagnosed between 5 years before and 15 months after the diagnosis of type 2 diabetes. A macrovascular disease was considered being present at time of type 2 diabetes diagnosis if the condition was diagnosed any time before the diagnosis and during the year following the diagnosis of type 2 diabetes. For the detection of pre-diabetes, the WHO/International Expert Committee diagnostic criteria were adopted (FPG: 6.1–6.9 mmol/L, OGTT 7.8–11.1 mmol/L, HbA1c 42 to 47 mmol/mol or 6.0%–6.4%). FPG, fasting plasma glucose; OGTT, oral glucose tolerance test; T2D, type 2 diabetes.
Figure 1 Prevalence of microvascular (retinopathy and nephropathy) and macrovascular (acute coronary syndrome, cerebrovascular, and peripheral arterial disease) diseases present at time of the diagnosis of type 2 diabetes according to glycemic status in the 3 years before the diagnosis of type 2 diabetes. A microvascular disease was considered being present at time of type 2 diabetes diagnosis if the condition was diagnosed between 5 years before and 15 months after the diagnosis of type 2 diabetes. A macrovascular disease was considered being present at time of type 2 diabetes diagnosis if the condition was diagnosed any time before the diagnosis and during the year following the diagnosis of type 2 diabetes. For the detection of pre-diabetes, the WHO/International Expert Committee diagnostic criteria were adopted (FPG: 6.1–6.9 mmol/L, OGTT 7.8–11.1 mmol/L, HbA1c 42 to 47 mmol/mol or 6.0%–6.4%). FPG, fasting plasma glucose; OGTT, oral glucose tolerance test; T2D, type 2 diabetes.CC BY-NC · PubMed Central
Figure 2 Association between glycemic testing and detection of pre-diabetes and presence of microvascular disease at the time of diagnosis of type 2 diabetes. Adjusted ORs and 95% CIs have been estimated employing multivariable logistic regression models adjusted for age, sex, ethnicity (white, South Asian, black, other, unknown), smoking status (non-smoker, ex-smoker, smoker), total cholesterol, systolic and diastolic blood pressure, number of coexisting chronic conditions, number of primary care visits in the previous year, general practice index of multiple deprivation, and year of diagnosis of type 2 diabetes. AOR, adjusted odds ratio; T2D, type 2 diabetes.
Figure 2 Association between glycemic testing and detection of pre-diabetes and presence of microvascular disease at the time of diagnosis of type 2 diabetes. Adjusted ORs and 95% CIs have been estimated employing multivariable logistic regression models adjusted for age, sex, ethnicity (white, South Asian, black, other, unknown), smoking status (non-smoker, ex-smoker, smoker), total cholesterol, systolic and diastolic blood pressure, number of coexisting chronic conditions, number of primary care visits in the previous year, general practice index of multiple deprivation, and year of diagnosis of type 2 diabetes. AOR, adjusted odds ratio; T2D, type 2 diabetes.CC BY-NC · PubMed Central
Figure 3 Association between glycemic testing and detection of pre-diabetes and presence of macrovascular disease at the time of diagnosis of type 2 diabetes. Adjusted ORs and 95% CIs have been estimated employing multivariable logistic regression models adjusted for age, sex, ethnicity (white, South Asian, black, other, unknown), smoking status (non-smoker, ex-smoker, smoker), total cholesterol, systolic and diastolic blood pressure, number of coexisting chronic conditions, number of primary care visits in the previous year, general practice index of multiple deprivation, and year of diagnosis of type 2 diabetes. AOR, adjusted odds ratio; T2D, type 2 diabetes.
Figure 3 Association between glycemic testing and detection of pre-diabetes and presence of macrovascular disease at the time of diagnosis of type 2 diabetes. Adjusted ORs and 95% CIs have been estimated employing multivariable logistic regression models adjusted for age, sex, ethnicity (white, South Asian, black, other, unknown), smoking status (non-smoker, ex-smoker, smoker), total cholesterol, systolic and diastolic blood pressure, number of coexisting chronic conditions, number of primary care visits in the previous year, general practice index of multiple deprivation, and year of diagnosis of type 2 diabetes. AOR, adjusted odds ratio; T2D, type 2 diabetes.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Ashra NB , Spong R , Carter P , et al . A systematic review and metaanalysis assessing the effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes mellitus in routine practice. London, the UK: Public Health England, 2015.

Cited by

Sorted by citations

See all 103

Metadata

Authors
Palladino, R., Tabak, A. G., Khunti, K., Valabhji, J., Majeed, A., Millett, C., & Vamos, E. P.
Affiliations
  • Imperial College London (GB)
  • Department of Epidemiology and Public Health, University College London, London, UK
  • University of Leicester (GB)
  • Imperial College Healthcare NHS Trust (GB)
Corresponding author
Palladino, Raffaele
Venue
BMJ Open Diabetes Research & Care
Publisher
BMJ
Published
2020-04
Volume
8
Issue
1
Pages
e001061
ISSN
2052-4897 (ISSN-L)
OpenAlex
W3019785267
Cited by
98
References
50
Citations by year
2026: 12 · 2025: 11 · 2024: 25 · 2023: 15 · 2022: 18 · 2021: 10 · 2020: 7
FWCI
9.43
Type
journal article
Language
en
Open access
Locations
  • BMJ Open Diabetes Research & Care (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UCL Discovery (University College London) (submittedVersion)
  • Figshare (submittedVersion, cc-by-nc)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc)
  • Spiral (Imperial College London) (submittedVersion, cc-by-nc)
Funders
  • National Institute for Health and Care Research
  • Department of Health and Social Care
  • Imperial College London
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
prediabetes, type 2 diabetes, newly diagnosed diabetes, microangiopathy, macroangiopathy, diabetic retinopathy, diabetic nephropathy, acute coronary syndrome, cerebrovascular disease, peripheral arterial disease, glycemic status, vascular complications, screening
MeSH terms
Blood Glucose, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Humans, Prediabetic State, Vascular Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review